NCT00276380 - A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Stroke, AcuteNeurological Impairment

Interventions

DRUG

EGb761

EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.

DRUG

Placebo

Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.

DRUG

Acetylsalicylic acid

Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.

Trial Locations (10)

CMUJ Krakov, Krakow

Institul de Boli Cerebro Vascular, Bucharest

Russian State Medical University - Neurology and Neurosurgery Clinic, Moscow

Russian State Medical University - Dept Fundamental Neurology & Neurosurgery, Moscow

Ural State Medical Academy, Yekaterinburg

Faculty of Medicine in Hradec Kralove, Hradec Králové

General Faculty Hospital, Prague

Department and Clinic of Neurology of the Old Age, Katowice

Postgraduate Medical Teaching Center, Warsaw

Spitalul Universitar de Urgenta, Bucharest